RAMONA SEQUEIRA MAY SOON BE CHAIRPERSON OF PHRMA BOARD

HIGHLIGHTS

  • Ramona Sequeira has been elected as chairperson of PhRMA Board and she may take over the charge soon.
  • Vas Narasimhan has become the PhRMA Treasurer.

The Pharmaceutical Research and Manufacturers of America (PhRMA) has elected two new officers to its board of directors. Ramona Sequeira, president of Takeda Pharmaceuticals USA, Inc. was named chair-elect. She is likely to take charge of Chairperson soon. In past, Sequeira has held the position of board treasurer. When she assumes the role of board chair next year, she is going to be the first woman in PhRMA’s history to do so. PhRMA’s board has also elected Vas Narasimhan as board treasurer. Narasimhan is the Managing Director (M.D.), and Chief Executive Officer (CEO) of Novartis.

Stephen J. Ubl, president and CEO of PhRMA, said that PhRMA and the biopharmaceutical research companies represented in the board were focused on the critical issues that mattered to the American people. Ubl said that companies could deliver the solutions that were necessary to get COVID-19 under control.

Sequeira said that over the past year, people witnessed the benefits of innovative science as the biopharmaceutical research companies worked together to address one of the greatest health care challenges which was coronavirus. Sequeira talked about looking forward to work with her new colleagues and stakeholders across the health care system to continue advocating for policies that not only prioritized the interests of patients, but also fostered public trust in science and the industry of biopharmaceutical research.

Narasimhan said that after the largest and fastest mobilization of global scientific capabilities against a pandemic that turned out to be the biggest public health crisis of modern times, the importance of the biopharmaceutical industry and the need to address longstanding health disparities. Talking about taking a collaborative approach, Narasimhan expressed eagerness to work with leaders across government to find solutions that could lower the financial burden on patients and increased transformative biomedical innovation.

, , ,